Hernández MS, Díaz MG

Language: Spanish
References: 0
Page: 109-114
PDF size: 76.82 Kb.

ABSTRACT

The lung hypertension is an illness of bad presage whose survive doesn’t surpass the 8 years. The current treatment has two slopes: the antihypertensive oral and the inhaled vasodilator. The primary lung arterial hypertension (HAP) it is a pathological state in which the lung arterial pressure surpasses the 25 mmHg in rest, without a cardiac illness exists or lung clinically important; three elements combine to produce an increase of the lung vascular resistance: vasoconstrictor, reshaping of the wall and thrombosis in situ. However, it is still to clarify if these dysfunctions are the cause or the effect of the illness. The clinical symptom is characterized by dyspnea, fatigue, angina and syncope. The right catheter is a given fundamental study its diagnostic implications, prediction and therapeutic. Considerable progresses have been achieved in the last 15 years, the initial answer to the vasodilators administration identify the patients that have probabilities of responding to the long term oral treatment using medications like adenosine, nifedipine, diltiazen or in its case, nitric oxide. This therapeutic challenge implies the nurse personnel’s active participation which has to carry out a valuation continuous of the patient’s hemodynamic data that could evidence alterations in the systemic arterial pressure and at the same time to plan in an opportune way its interventions to avoid complications.